SOLA Biosciences to Establish Central Development Hub in Japan with AMED Funding
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
SOLA Biosciences Japan GK, the wholly owned subsidiary of SOLA Biosciences Inc., announced it is establishing a central development hub in Japan. The company received a grant of approximately 6 billion yen from the Japan Agency for Medical Research and Development (AMED) under the Strengthening Program for Pharmaceutical Startup Ecosystem. This funding supports the development of SOL-257, SOLA's gene therapy program targeting ALS.
From manilatimes.net
Why it matters
The grant establishes a significant financial partnership between AMED and SOLA, bolstering the biotech development ecosystem in Japan. The hub will coordinate efforts with SOLA's U.S. team, academic institutions, and various global partners. The program is backed by investors including Curie.Bio and UTEC.
From manilatimes.net
Who's involved
- SolaBoston-based company establishing the development hub in Japan.
- Japan Agency for Medical Research and DevelopmentAgency that awarded the grant to SOLA for its gene therapy program.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- SolaSpeculative
The company could utilize the funding to advance its gene therapy program and expand its global research network.
Keep exploring
The entities involved
-
Sola
Dutch company
Nothing else this week.
-
Tokyo
capital and largest city of Japan
-
Japan Agency for Medical Research and Development
facility in Tokyo, Japan
Nothing else this week.